Home / Products / Mid & Long Term Vascular Access / Ports / seesite™ 3000 Series Mini Ports

seesite™ 3000 Series Mini Ports

Mini hybrid totally implantable venous access device

seesite™ 3000 series are our mini lightweight, hybrid port with titanium reservoir and POM casing. Unique radiopaque marking with max flow rate identification and a max 325psi & 3ml/s with 19G or 20G CT Huber needle.

Clear
Commercial Code: N/A

About Product

seesite™ is an easily administered implantable lightweight, hybrid port for adults and paediatrics requiring injectable medicines. It is positioned directly beneath the skin, usually in a discrete easily accessible place (chest level) with unique radiopaque marking with max flow rate identification. Medicines then reach the blood circulation directly after simply puncturing the site through the skin.

seesiteunique and innovative radiopaque marking:

  • Radiopaque marking detectable by X-ray
  • Silicone filled suture holes
  • Each graduation = 1 mL/s
  • Radiopaque connecting ring
  • Easy to check correct positioning

 

Other advantages include:

  • Hybrid: titanium and POM(1) port for adults and paediatrics.
  • Profile-shaped design
  • Easy to connect
  • Titanium-POM combination: low weight
  • Titanium reservoir: compatibility with antineoplastic agents
  • Radiopaque connecting ring
  • MRI conditional & CT compatible

seesite

Includes safety Huber needle, echogenic puncture needle and Raulerson device.

In addition to the accessories all kits contain: an implantable port, a radiopaque catheter and two connection rings (only one for pre-connected references).

UOI Units: Singles

UOI: 1

Contains Latex: No

Contains DEHP: No

Sterile Medical Device: Yes

Manufacturer: Vygon SA

Similar Products

Events

There are currently no related events to this product.

News

Vygon Group acquires Pilot, specialist in ECG central venous catheter tip location and navigation devices

Vygon Group, a specialist single-use medical devices group, today announces its acquisition of Italian firm Pilot, which specialises in ECG guidance devices.

Read More

Drug stability data now available for up to 18hr administration of Ceftazidime

In order to assign a shelf life to a prepared product in an elastomeric device, comprehensive stability tests must be completed.

Read More

Vascular Access Decision Matrix

We’ve made a handy little device selection matrix to help you find the right IV lines for your patients. To …

Read More